Upgrade call on iShares MSCI Europe Financials ETF (EUFN): low 8.8x P/E, 4.31% yield and 200-day support after 11% drop—read ...

Roche’s vamikibart shows 1-year vision gains in Phase 3 uveitic macular edema trials, offering a non-steroid alternative; see ...

From a performance perspective, the equity market is entering the most bullish period in the four-year presidential cycle.

NextGen Infrastructure Income Fund offers a 13% yield, blending traditional and next-gen infrastructure assets. Read the full ...

The forecast follows an extraordinary year for capital raising. U.S. companies have issued approximately $431 billion in ...

We exited The Trade Desk in the quarter. Its revenue growth continues to lag that of peers such as Amazon, Meta, Google, and ...

Out of favor small caps and industries could see their strongest gains in the October breakout cycle. Most of the gains this ...

Byrna Technologies (BYRN) is downgraded from Buy to Hold due to persistent sales declines despite improved gross margins.

Ovintiv (OVV) analysis: strong credit profile and investment grade stability, but better opportunities may exist.

Phase 3 encaleret results in ADH1 show symptom and bone-health gains; FDA priority review decision May 2027—read key investor ...

The New York Stock Exchange and Nasdaq will remain open for their regular trading sessions, from 9:30 a.m. to 4 p.m. Eastern ...

Coca-Cola's cash flows have been volatile from refranchising, acquisitions, and large tax payments. See why I rate KO stock a ...